Company Announces Discontinuation of Development of Oral Taxane Tesetaxel
Posted: Thursday, March 25, 2021
Odonate Therapeutics has announced it is discontinuing development of its oral taxane tesetaxel, which was being studied as a treatment of patients with metastatic breast cancer, and will close the company’s operations. The decision came following feedback from the U.S. Food and Drug Administration in a pre–new drug application meeting, where it became apparent the drug’s approval was unlikely. The company plans to work with clinical sites to transition patients in ongoing tesetaxel clinical studies to appropriate alternative therapies.
“We thank the investigators, study team personnel, and especially the patients and their caregivers for their endeavors to improve treatments for patients with breast cancer,” said Kevin Tang, Chief Executive Officer of Odonate Therapeutics.
